Guerbet

Research Guerbet (0ELV) on Bullrun: P/E 3.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker0ELV
• ExchangeLSE
• CountryFrance
• CurrencyEUR
• P/E3.4
• Financial periodFY2025
• RevenueEUR 786.44M
• Revenue growth-6.5%
• Net income-EUR 112.65M
• Free cash flowEUR 51.23M

Valuation Snapshot

P/E is 3.4.

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.

Frequently asked questions

What is Guerbet's P/E ratio?

Guerbet's price-to-earnings (P/E) ratio is 3.4.

What does Guerbet do?

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations;